{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:27:59Z","timestamp":1762324079588,"version":"3.41.0"},"reference-count":160,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323461443"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/b978-0-323-46144-3.00027-1","type":"book-chapter","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T16:27:10Z","timestamp":1492792030000},"page":"749-774","source":"Crossref","is-referenced-by-count":9,"title":["Current aspects of breast cancer therapy and diagnosis based on a nanocarrier approach"],"prefix":"10.1016","author":[{"given":"Fab\u00edola S.G.","family":"Pra\u00e7a","sequence":"first","affiliation":[]},{"given":"H. Susana","family":"Marinho","sequence":"additional","affiliation":[]},{"given":"M. B\u00e1rbara F.","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Rog\u00e9rio","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"M. Lu\u00edsa","family":"Corvo","sequence":"additional","affiliation":[]},{"given":"Wanessa S.G.","family":"Medina","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clbc.2013.09.006","article-title":"Clinicopathologic implications of EpCAM and Sox2 expression in breast cancer","volume":"14","author":"Abd El-Maqsoud","year":"2014","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0015","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1016\/j.biomaterials.2009.07.008","article-title":"Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy","volume":"30","author":"Acharya","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.seminoncol.2004.08.010","article-title":"Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials","volume":"31","author":"Alberts","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Atkinson","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0035","first-page":"1745","article-title":"A general mechanism for microsomal activation of quinone anticancer agents to free radicals","volume":"38","author":"Bachur","year":"1978","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0040","first-page":"401","article-title":"Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer","volume":"17","author":"Barbati","year":"1997","journal-title":"Anticancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0045","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1517\/14656566.3.12.1739","article-title":"Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy","volume":"3","author":"Batist","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0050","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000123851","article-title":"TP53 status and response to chemotherapy in breast cancer","volume":"75","author":"Bertheau","year":"2008","journal-title":"Pathobiology"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.biomaterials.2015.01.007","article-title":"PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal action polymerization through miR-34a","volume":"51","author":"Bhattacharya","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0065","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1186\/bcr2811","article-title":"p53 mutant breast cancer patients expressing p53 gamma\u00a0have as good a prognosis as wild-type p53 breast cancer patients","volume":"13","author":"Bourdon","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-1-60327-492-0_13","article-title":"Breast cancer screening and biomarkers","volume":"472","author":"Brooks","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev.ph.42.030180.001545","article-title":"Transport pathways in capillaries: in search of pores","volume":"42","author":"Bundgaard","year":"1980","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0080","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1093\/annonc\/mdh393","article-title":"Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer","volume":"15","author":"Chan","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0090","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14796694.1.1.37","article-title":"Cancer biomarkers: knowing the present and predicting the future","volume":"1","author":"Chatterjee","year":"2005","journal-title":"Future Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0095","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s10549-009-0671-z","article-title":"Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases","volume":"123","author":"Cimino","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.phrs.2010.01.013","article-title":"HER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent 1010 implications in nanomedical approaches","volume":"62","author":"Colombo","year":"2010","journal-title":"Pharmacol. Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0105","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3816\/CBC.2010.n.036","article-title":"Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer","volume":"10","author":"Conlin","year":"2010","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1359-6349(10)70002-1","article-title":"Nanoparticle albumin-bound (nabTM)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer","volume":"8","author":"Cortes","year":"2010","journal-title":"Eur. J. Cancer Suppl."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0115","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0959-8049(02)00067-9","article-title":"Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer\u2014results of the analysis of 670 patients with 11\u00a0years of follow-up","volume":"38","author":"Costa","year":"2002","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.canlet.2007.09.011","article-title":"Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target","volume":"258","author":"Coyle","year":"2007","journal-title":"Cancer Lett."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/1568011054866964","article-title":"Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde","volume":"5","author":"Cutts","year":"2005","journal-title":"Curr. Med. Chem. Anticancer Agents"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0135","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","article-title":"To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery","volume":"148","author":"Danhier","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2008.09.086","article-title":"Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation","volume":"133","author":"Danhier","year":"2009","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0145","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.bbagen.2011.07.016","article-title":"The transferrin receptor and the targeted delivery of therapeutic agents against cancer","volume":"1820","author":"Daniels","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0150","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.colsurfb.2015.09.013","article-title":"Enhanced toxicity and cellular uptake of methotrexate-conjugated nanoparticles in folate receptor-positive cells by decorating with acid-conjugated tocopherol polyethylene glycol 1000 succinate","volume":"136","author":"Dhanahiranpruk","year":"2015","journal-title":"Colloids Surf. B"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1083\/jcb.27.3.545","article-title":"Inhibiting effect of the new cytotoxic antibiotic daunomycin on nucleic acids and mitotic activity of HeLa cells","volume":"27","author":"Di","year":"1965","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7150\/jca.8925","article-title":"Far Beyond the usual biomarkers in breast cancer: a review","volume":"5","author":"Dos Anjos Pultz","year":"2014","journal-title":"J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0165","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1373\/clinchem.2005.059832","article-title":"Serum tumor markers in breast cancer: are they of clinical value?","volume":"52","author":"Duffy","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0170","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.colsurfb.2014.09.029","article-title":"Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery","volume":"123","author":"Eloy","year":"2014","journal-title":"Colloids Surf. B"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0175","unstructured":"European Medicines Agency, 2010. EPAR Summary for the Public. EMA, 281962. EMEA\/H\/C\/297."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0180","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/1471-2407-11-486","article-title":"Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment","volume":"11","author":"Fasching","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0185","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"year":"2014","series-title":"Regulatory aspects of oncologicals: nanosystems main challenges","author":"Gaspar","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0190"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0195","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","article-title":"Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation","volume":"37","author":"Gelderblom","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0200","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0205","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1515\/CCLM.2002.047","article-title":"Serum cytokeratin fragment 21.1 (CYFRA 21. 1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15. 3 (CA 15. 3) and carcinoembryonic antigen (CEA)","volume":"40","author":"Giovanella","year":"2002","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0210","unstructured":"GLOBOCAN, 2012. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. International Agency for Research on Cancer- IARC 2015, Lyon, France. Available from: http:\/\/www.wcrf.org\/int\/cancer-facts-figures\/worldwide-data."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0215","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0220","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ejso.2009.01.014","article-title":"Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2\/neu-negative invasive breast cancer: efficacy and safety in a phase II pilot study","volume":"35","author":"Greil","year":"2009","journal-title":"EJSO"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0225","first-page":"105","article-title":"Urokinase-type plasminogen activator system and breast cancer (review)","volume":"14","author":"Han","year":"2005","journal-title":"Oncol. Rep."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0230","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0235","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","article-title":"American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer","volume":"25","author":"Harris","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0240","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ijc.22811","article-title":"Folate receptor overexpression is associated with poor outcome in breast cancer","volume":"121","author":"Hartmann","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0245","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11095-010-0178-7","article-title":"Clinical developments in nanotechnology for cancer therapy","volume":"28","author":"Heidel","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0250","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ijc.11488","article-title":"Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells","volume":"107","author":"Hemsen","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0255","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nature05630","article-title":"Multiple molecular mechanisms for multidrug resistance transporters","volume":"446","author":"Higgins","year":"2007","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0260","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of\u00a0transport pathways in tumor vessels: role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0265","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2010.01.036","article-title":"Biomarkers of chemotherapy resistance\u00a0in breast cancer identified by proteomics: current status","volume":"294","author":"Hodgkinson","year":"2010","journal-title":"Cancer Lett."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0270","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(03)13308-9","article-title":"Gene expression predictors of breast cancer outcomes","volume":"361","author":"Huang","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0275","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","article-title":"Lipid nanocapsules: a new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0280","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"issue":"11","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0285","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0290","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0295","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1158\/1535-7163.1505.3.12","article-title":"Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment","volume":"3","author":"Jhaveri","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0300","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s11095-009-9889-z","article-title":"Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells","volume":"26","author":"Jin","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0305","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1039\/b920570p","article-title":"PEGylated polymers for medicine: from conjugation to self-assembled systems","volume":"46","author":"Joralemon","year":"2010","journal-title":"Chem. Commun."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0310","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.metabol.2014.10.027","article-title":"Biomarkers for personalized oncology: recent advances and future challenges","volume":"64","author":"Kalia","year":"2015","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0800","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.patbio.2015.07.005","article-title":"What common biomarkers characterize a triple-negative profile in breast cancer?","volume":"63","author":"Kallel","year":"2015","journal-title":"Pathol. Biol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/1875933501103010038","article-title":"Nanoscale drug delivery and hyperthermia: the materials design and preclinical and clinical testing of low temperature-sensitive liposomes used in combination with mild hyperthermia in the treatment of local cancer","volume":"3","author":"Landon","year":"2011","journal-title":"Open Nanomed. J."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0320","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jsbmb.2007.09.019","article-title":"Integration of progesterone receptor action with rapid signaling events in breast cancer models","volume":"108","author":"Lange","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10549-007-9591-y","article-title":"Multicenter phase II trial of Genexol-PM, a cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer","volume":"108","author":"Lee","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0330","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.5012\/bkcs.2010.31.8.2265","article-title":"Development of worm-like polymeric drug carriers with multiple ligands for targeting heterogeneous breast cancer cells","volume":"31","author":"Lee","year":"2010","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0335","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.bbagen.2007.01.017","article-title":"Biomarkers for early detection of breast cancer: what, when, and where?","volume":"1770","author":"Levenson","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0340","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/351453a0","article-title":"The P53 tumor suppressor gene","volume":"351","author":"Levine","year":"1991","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0345","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0169-409X(02)00042-X","article-title":"Folate-mediated delivery of macromolecular anticancer therapeutic agents","volume":"54","author":"Lu","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0350","first-page":"219","article-title":"Immunohistochemical detection of progesterone receptors in breast invasive ductal carcinomas: a correlative study of 942 cases","volume":"4","author":"MacGrogan","year":"1996","journal-title":"Appl. Immunohistochem."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0355","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","article-title":"Liposomes and nanoparticles: nanosized vehicles for drug delivery\u00a0in cancer","volume":"30","author":"Malam","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0360","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.critrevonc.2015.08.011","article-title":"Treatment of HER2 positive advanced breast cancer with T-DM1: a review of the\u00a0literature","volume":"97","author":"Martinez","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0365","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer-chemotherapy\u2014mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0370","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2174\/138161211796718152","article-title":"Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic","volume":"17","author":"Mazar","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.mpdhp.2009.07.002","article-title":"Breast cancer subtypes and molecular biomarkers","volume":"15","author":"McCafferty","year":"2009","journal-title":"Diagn. Histopathol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0380","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.pharmthera.2006.10.003","article-title":"How can we best use structural information on Pglycoprotein to design inhibitors?","volume":"113","author":"McDevitt","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0385","first-page":"99","article-title":"Albumin-bound formulation of paclitaxel (Abraxane (R) ABI-007) in the treatment of breast cancer","volume":"4","author":"Miele","year":"2009","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0390","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0395","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.clbc.2011.03.007","article-title":"A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer","volume":"11","author":"Mirtsching","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0400","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.drudis.2010.08.006","article-title":"Cancer nanotechnology: application of nanotechnology in cancer therapy","volume":"15","author":"Misra","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0405","first-page":"224","article-title":"Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy","volume":"1815","author":"Mukhopadhyay","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0410","first-page":"2404","article-title":"Evidence for inhibition of growth related to compromised DNA-synthesis in the interaction of daunorubicin with H-35 rat hepatoma","volume":"48","author":"Munger","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0415","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2217\/nnm.11.93","article-title":"Pglycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells","volume":"7","author":"Navarro","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0420","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bjc.6600344","article-title":"A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer","volume":"87","author":"O\u2019Byrne","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0425","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ejso.2015.01.030","article-title":"Changes in estrogen receptor, HER2 and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence","volume":"41","author":"Okumura","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0430","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-05-1029","article-title":"The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer","volume":"12","author":"Olivier","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0435","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/0008-5472.CAN-04-0754","article-title":"EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy","volume":"64","author":"Osta","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0440","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1016\/j.biomaterials.2010.06.024","article-title":"The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability","volume":"31","author":"Paillard","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0445","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.biomaterials.2008.02.020","article-title":"Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles","volume":"29","author":"Pan","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0450","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","article-title":"Glycolysis inhibition for anticancer treatment","volume":"25","author":"Pelicano","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0455","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0378-4347(97)00362-9","article-title":"On the use of ion-pair chromatography to elucidate doxorubicin release mechanism from polyalkylcyanoacrylate nanoparticles at the cellular level","volume":"702","author":"Pepin","year":"1997","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0460","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0465","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1517\/14656561003796562","article-title":"Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel","volume":"11","author":"Petrelli","year":"2010","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0470","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/mp049970+","article-title":"Nanoparticle-mediated wild-type p53 gene delivery results in sustained antiproliferative activity in breast cancer cells","volume":"1","author":"Prabha","year":"2004","journal-title":"Mol. Pharm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0475","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.1158\/0008-5472.CAN-09-0854","article-title":"Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells","volume":"69","author":"Raina","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0480","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/modpathol.3800445","article-title":"Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer","volume":"18","author":"Rakha","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0485","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/bjc.2012.41","article-title":"HER2\/neu and Ki-67 expression predict noninvasive recurrence following breast-conserving therapy for ductal carcinoma in situ","volume":"106","author":"Rakovitch","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0805","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1040-8428(00)00107-4","article-title":"Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer","volume":"37","author":"Ranson","year":"2001","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0490","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cdp.2005.07.004","article-title":"Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status","volume":"29","author":"Rusiecki","year":"2005","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0495","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S1359-6446(03)02903-9","article-title":"Nanotech approaches to delivery and imaging drug","volume":"8","author":"Sahoo","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0500","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1021\/mp050032z","article-title":"Enhanced antiproliferative activity of transferrin conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention","volume":"2","author":"Sahoo","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0505","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.nano.2006.11.008","article-title":"The present and future of nanotechnology in human health care","volume":"3","author":"Sahoo","year":"2007","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0510","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.clbc.2015.01.005","article-title":"Proliferation determined by Ki-67 defines pathologic response to neoadjuvant trastuzumab-based chemotherapy in HER2-positive breast cancer","volume":"15","author":"S\u00e1nchez-Mu\u00f1oz","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0515","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1158\/0008-5472.CAN-08-2708","article-title":"Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion","volume":"69","author":"Sankpal","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0520","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2217\/nnm.13.8","article-title":"Therapeutic nanoparticles in clinics and under clinical evaluation","volume":"8","author":"Schutz","year":"2013","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0525","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2015.04.009","article-title":"A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index","volume":"208","author":"Scomparin","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0530","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0535","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.107.127704","article-title":"Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells","volume":"324","author":"Shen","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0540","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clbc.2014.09.010","article-title":"The efficacy and safety of preoperative chemotherapy with triweekly Abraxane and cyclophosphamide followed by 5-fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial","volume":"15","author":"Shigematsu","year":"2015","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0545","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1083\/jcb.79.1.27","article-title":"Open junctions in the endothelium of the postcapillary venules of the diaphragm","volume":"79","author":"Simionescu","year":"1978","journal-title":"J. Cell Biol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0550","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/PAI.0b013e318209716e","article-title":"Differential expression of transferrin receptor (TfR) in a 1425 spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma","volume":"19","author":"Singh","year":"2011","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0555","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.ejca.2004.08.021","article-title":"Molecular portraits of breast cancer: tumour subtypes as distinct disease entities","volume":"40","author":"Sorlie","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0560","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0565","first-page":"183","article-title":"The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast","volume":"32","author":"Su","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0570","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biomaterials.2007.09.038","article-title":"Multifunctional 1450 poly(d,l-lactide-co-glycolide)\/montmorillonite (PLGA\/MMT) nanoparticles decorated by trastuzumab for targeted chemotherapy of breast cancer","volume":"29","author":"Sun","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0575","first-page":"176","article-title":"Genomic and proteomic biomarkers for cancer: a multitude of opportunities","volume":"1796","author":"Tainsky","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0580","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.msec.2015.01.033","article-title":"Co-delivery of docetaxel and poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment","volume":"49","author":"Tang","year":"2015","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/14737140.2.2.143","article-title":"Caelyx\/doxil for the treatment of metastatic ovarian and breast cancer","volume":"2","author":"Tejada-Berges","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0590","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase-II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0595","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrd1632","article-title":"Recent advances with liposomes as pharmaceutical carriers","volume":"4","author":"Torchilin","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0600","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.addr.2010.03.011","article-title":"Tumor delivery of macromolecular drugs based on the EPR effect","volume":"63","author":"Torchilin","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0605","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/bjc.2011.516","article-title":"Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer","volume":"106","author":"Tsang","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0610","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1016\/j.biomaterials.2013.06.042","article-title":"The eradication of breast cancer cells and stem cells by 8-hydroxyquinoline-loaded hyaluronan modified mesoporous silica nanoparticle-supported lipid bilayers containing docetaxel","volume":"34","author":"Wang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0615","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3322\/CA.2007.0003","article-title":"Application of nanotechnology in cancer therapy and imaging","volume":"58","author":"Wang","year":"2008","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0620","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1677\/ERC-10-0136","article-title":"Current and emerging biomarkers in breast cancer: prognosis and prediction","volume":"17","author":"Weigel","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0625","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.breast.2009.02.009","article-title":"Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients","volume":"18","author":"Wiesner","year":"2009","journal-title":"Breast"},{"issue":"25","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0630","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.cca.2015.05.022","article-title":"Quantitative assessment of human serum transferring receptor in breast cancer patients pre- and post-chemotherapy using peptide immunoaffinity enrichment coupled with targeted proteomics","volume":"448","author":"Xu","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0635","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcis.2010.05.022","article-title":"Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells","volume":"351","author":"Yallapu","year":"2010","journal-title":"J. Colloid Interf. Sci."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0640","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1158\/1078-0432.CCR-08-3289","article-title":"Receptor-targeted nanoparticles for in vivo imaging of breast cancer","volume":"15","author":"Yang","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0645","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0650","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clbc.2011.04.002","article-title":"Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2(+) breast cancer","volume":"11","author":"Yardley","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0655","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S1470-2045(06)70793-8","article-title":"Emerging use of nanoparticles in diagnosis and treatment of breast cancer","volume":"7","author":"Yezhelyev","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0660","first-page":"3352","article-title":"Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0665","first-page":"4564","article-title":"Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows","volume":"54","author":"Yuan","year":"1994","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/B978-0-323-46144-3.00027-1_bib0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/tlo.09250","article-title":"Targeting p53 for novel anticancer therapy","volume":"3","author":"Zhen","year":"2010","journal-title":"Transl. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0675","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2010.02.008","article-title":"Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells","volume":"390","author":"Zheng","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0680","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients","volume":"96","author":"Azambuja","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0685","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.nano.2010.10.004","article-title":"960 Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes","volume":"7","author":"Bedi","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0690","doi-asserted-by":"crossref","first-page":"17635","DOI":"10.1074\/jbc.M800109200","article-title":"Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells","volume":"283","author":"Bourguignon","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0695","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2010.08.001","article-title":"Small-molecule delivery by nanoparticles for anticancer therapy","volume":"16","author":"Chen","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0700","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1524-4741.2007.00483.x","article-title":"Assessment of biomarker expression in predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer","volume":"13","author":"Chieng","year":"2007","journal-title":"Breast J."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0705","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/ijc.24890","article-title":"Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis","volume":"126","author":"Elazar","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0710","unstructured":"Food and Drug Administration Center for Drug Evaluation and Research (CDER). Oncologic Drugs Advisory Committee. Discussion of Supplemental NDA (sNDA), DOXIL (Doxorubicin HCL Liposome Injection) for Intravenous Infusion. Centocor Ortho Biotech Products, L.P., Proposed Indication in Combination with Docetaxel for the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Anthracycline Treatment. Available from: http:\/\/www.fda.gov\/AdvisoryCommittees\/Calendar\/ucm164972.htm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0715","doi-asserted-by":"crossref","first-page":"R23","DOI":"10.1186\/bcr2249","article-title":"Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer","volume":"11","author":"Jacquemier","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0720","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1155\/2012\/915375","article-title":"Combination drug delivery approaches in metastatic breast cancer","volume":"2012","author":"Lee","year":"2012","journal-title":"J. Drug Deliv."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0725","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/138527210790069839","article-title":"Advances in bioconjugation","volume":"14","author":"Kalia","year":"2010","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0730","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mds024","article-title":"European cancer mortality predictions for the year 2012","volume":"23","author":"Malvezzi","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0735","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/annonc\/mdr024","article-title":"Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM\/2004-05 study","volume":"22","author":"Martin","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0740","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","article-title":"Global cancer statistics in the year 2000","volume":"2","author":"Parkin","year":"2001","journal-title":"Lancet Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0745","doi-asserted-by":"crossref","first-page":"430","DOI":"10.18632\/oncotarget.295","article-title":"Is nanomedicine still promising?","volume":"2","author":"Peiris","year":"2011","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0750","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/annonc\/mdq319","article-title":"Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24\/06)","volume":"22","author":"Rochlitz","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0755","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1016\/j.ejca.2010.09.019","article-title":"Up-to-date estimates of breast cancer survival for the years 2000\u20132004 in 11 European countries: the role of screening and a comparison with data from the United States","volume":"46","author":"Rosso","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0760","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"Cancer J. Clin."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0765","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yexmp.2008.12.004","article-title":"Nanoparticle-based targeted drug delivery","volume":"86","author":"Singh","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0770","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the Her-2\/Neu proto-oncogene in human-breast and ovarian-cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0775","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1477-7819-8-51","article-title":"The clinical behavior of mixed ductal\/lobular carcinoma of the breast: a clinicopathologic analysis","volume":"8","author":"Suryadevara","year":"2010","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0780","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.11188","article-title":"Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors, a surrogate marker?","volume":"97","author":"Trihia","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0785","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijpharm.2010.06.046","article-title":"Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy","volume":"397","author":"Urbinati","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0790","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1200\/JCO.2005.07.501","article-title":"Proliferation marker Ki-67 in early breast cancer","volume":"23","author":"Urruticoechea","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/B978-0-323-46144-3.00027-1_bib0795","first-page":"57","article-title":"Targeted therapy for cancer","volume":"2","author":"Wu","year":"2006","journal-title":"J. Cancer Mol."}],"container-title":["Nanostructures for Cancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323461443000271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323461443000271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:39:11Z","timestamp":1750203551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323461443000271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780323461443"],"references-count":160,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-46144-3.00027-1","relation":{},"subject":[],"published":{"date-parts":[[2017]]}}}